Polyendocrine Metabolic Ovarian Syndrome Market Summary

• According to DelveInsight’s analysis, the PMOS market size was found to be ~USD 3,500 million in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• The evolving understanding of PMOS as a multisystem condition involving hormonal imbalance, metabolic dysfunction, fertility impairment, and increased long-term risks of diabetes and cardiovascular complications is expected to drive greater disease awareness and healthcare attention.
• Among the EU4 and the UK, Germany had the highest (~25%) number of diagnosed prevalent cases of PMOS, followed by UK, while Spain reported the lowest cases.
• Currently, there is no approved therapy specifically for PMOS in the 7MM.
• Management relies primarily on off-label use of established therapies, including metformin for insulin resistance, combined oral contraceptives for menstrual regulation and hyperandrogenic symptoms, anti-androgens for androgen-related manifestations, and ovulation induction agents for infertility management.
• The recognition of Polycystic Ovary Syndrome (PCOS) as a broader Polyendocrine Metabolic Ovarian Syndrome (PMOS) is expected to reshape disease management by shifting focus from symptom control toward comprehensive metabolic and hormonal management. 
• The PMOS pipeline remains limited, with only a small number of early-stage programs under investigation. Currently, AKP-009 (ASKA Pharmaceutical) represents one of the emerging targeted candidates in development, with the program currently at the preclinical stage in Japan.
• Growing awareness of the disease burden, diagnostic challenges, and long-term metabolic consequences may support expansion of research initiatives and clinical innovation.
• Despite a large patient population and substantial unmet need, market development may remain gradual due to diagnostic delays, heterogeneous disease presentation, and competition from inexpensive generic therapies currently used in clinical practice.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market Size and Forecast in the 7MM

• 2025 PMOS Market Size: USD 3,500 million
• 2036 Projected PMOS Market Size: USD XX million
• PMOS Growth Rate (2026–2036): 3% CAGR

DelveInsight's ‘Polyendocrine Metabolic Ovarian Syndrome (PMOS) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the PMOS, historical and forecasted epidemiology, as well as the PMOS market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The PMOS market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates PMOS patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in PMOS and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market

• Rising Disease Prevalence and Growing Awareness

Increasing recognition of PMOS as a common endocrine-metabolic disorder among women of reproductive age is driving greater diagnosis rates and demand for effective management options. Improved awareness among patients and healthcare providers, along with increased screening initiatives, is expected to expand the addressable patient population.

• Increasing Burden of Metabolic Complications

The strong association of PMOS with obesity, insulin resistance, Type 2 Diabetes (T2D), dyslipidemia, and cardiovascular risk is shifting disease management beyond reproductive symptoms toward long-term metabolic care. This is expected to increase adoption of insulin-sensitizing agents, weight-management therapies, and metabolic-targeted treatments.

• Healthcare System Focus on Chronic Disease Management

Recognition of PMOS as a lifelong condition with reproductive, metabolic, and psychological consequences is driving the need for continuous monitoring and multidisciplinary care, supporting sustained demand for therapeutic interventions.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Understanding and Treatment Algorithm

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Overview and Diagnosis

PCOS, officially renamed as PMOS in 2026, is one of the most common endocrine and metabolic disorders affecting women of reproductive age. The new terminology more accurately reflects the multisystem nature of the disease, recognizing that it extends beyond the ovaries and that many affected individuals do not have polycystic ovaries. PMOS is characterized by a complex interaction of hormonal imbalance, insulin resistance, chronic low-grade inflammation, and ovarian dysfunction, leading to hyperandrogenism, ovulatory dysfunction, and variable ovarian morphology. In addition to reproductive complications such as infertility and menstrual irregularities, the disorder is associated with obesity, T2D, dyslipidemia, hypertension, metabolic dysfunction-associated steatotic liver disease (MASLD), and psychological disorders, including anxiety and depression. Owing to its lifelong clinical burden, high prevalence, and broad metabolic implications, PMOS remains a significant public health challenge with substantial unmet medical needs, particularly given the absence of disease-specific approved therapies.

The diagnosis of PMOS, is based on a combination of clinical, biochemical, and imaging findings, as no single diagnostic test exists. The Rotterdam criteria remain the most widely accepted diagnostic standard, requiring the presence of at least two of the following after excluding other endocrine disorders: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. A comprehensive evaluation includes assessment of serum androgen levels, thyroid function, prolactin, and adrenal hormones to rule out alternative causes of menstrual irregularities and androgen excess. Given the syndrome's strong metabolic component, patients are also routinely screened for obesity, insulin resistance, impaired glucose tolerance or T2D, dyslipidemia, hypertension, and other cardiometabolic risk factors to guide long-term management.

Further details are provided in the report.

Current Polyendocrine Metabolic Ovarian Syndrome (PMOS) Treatment Landscape

There are currently no therapies specifically approved for the treatment of PMOS/PMOS, and management is individualized according to the patient's symptoms, metabolic status, and reproductive goals. Lifestyle modification, including weight reduction through dietary changes, regular physical activity, and behavioral interventions, remains the cornerstone of therapy and has been shown to improve ovulatory function, insulin sensitivity, and overall metabolic health. Pharmacological management primarily relies on off-label therapies, including combined oral contraceptives for menstrual regulation and hyperandrogenic symptoms, metformin for insulin resistance and metabolic abnormalities, and anti-androgens such as spironolactone for hirsutism and acne. For women seeking pregnancy, ovulation induction agents such as letrozole are recommended as first-line therapy, while clomiphene citrate and gonadotropins may be considered in selected patients. Despite the availability of these symptom-directed treatments, current management does not target the underlying pathophysiology of the disorder, underscoring the significant unmet need for disease-modifying and targeted therapeutic options.

Further details related to country-based variations are provided in the report.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Unmet Needs

The section “unmet needs of PMOS” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. PMOS remains significantly underdiagnosed due to heterogeneous clinical presentations
2. No therapy is currently approved specifically to modify the underlying disease mechanisms of PMOS
3. Limited high-quality clinical evidence and treatment guidelines hinder evidence-based clinical decision-making
4. The natural history and long-term progression of PMOS remain incompletely understood, making prognosis and treatment planning challenging, and others…..

Note: Comprehensive unmet needs insights in PMOS and their strategic implications are provided in the full report.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Epidemiology

Key Findings from PMOS Epidemiological Analysis and Forecast

• According to DelveInsight estimates, there were approximately 20 million diagnosed prevalent cases of PMOS in the 7MM in 2025. 
• Among the 7MM, US had the highest number of diagnosed prevalent cases, at around 9.4 million cases.
• Among the age-specific segment, the age group 26–35 had the highest (~45%) number of cases followed by the age group of 36–49 in the US in 2025.
• As per clinical manifestations, polycystic ovaries had the highest number of cases followed by hyperandrogenem in Japan in 2025.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Drug Analysis & Competitive Landscape

The PMOS drug chapter provides a detailed, market-focused review of the emerging pipeline across preclinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the PMOS treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the PMOS therapeutics market.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Pipeline Analysis

Ludaterone acetate (AKP-009): ASKA Pharmaceutical

Ludaterone acetate (AKP-009) is an investigational oral therapy being developed by ASKA Pharmaceutical for the treatment of PCOS. According to ASKA Pharmaceutical's development pipeline, the program is currently in the preparing clinical trials stage (pre-clinical), making it one of the few pipeline assets specifically targeting PCOS.

Note: Detailed emerging therapies assessment will be provided in the final report.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Key Players, Market Leaders and Emerging Companies

• ASKA Pharmaceutical, and others

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market Outlook

The PMOS treatment landscape remains highly fragmented, with no approved disease-specific therapies currently available. Management primarily relies on symptom-directed approaches, including lifestyle interventions, hormonal contraceptives, insulin-sensitizing agents, anti-androgen therapies, and fertility treatments, which are often used based on individual patient needs and clinical manifestations. The absence of targeted pharmacological options addressing the underlying endocrine and metabolic abnormalities represents a significant unmet need and creates opportunities for the development of novel therapies.

Among emerging pipeline candidates, ASKA Pharmaceutical is evaluating AKP-009, a preclinical-stage candidate being investigated for PCOS, representing one of the few targeted drug development efforts in this therapeutic area. If successful, AKP-009 could provide a disease-modifying approach by addressing key biological pathways involved in PCOS pathophysiology and may help overcome limitations associated with current symptomatic management. Tildacerfont was initially positioned as a groundbreaking non-steroidal therapy for classic Congenital Adrenal Hyperplasia (CAH) but Spruce Biosciences officially discontinued its CAH development program.

Ribupatide (HRS9531) is in clinical trial (Phase II) for PCOS currently in China, Kailera in its presentation anticipated to begin the global Phase III trials as early as 1H of 2027.

Overall, the PMOS market is expected to be driven by increasing disease recognition, rising prevalence of associated metabolic complications, unmet need for approved disease-specific therapies, and future innovation in targeted treatments. While the market currently remains dominated by off-label therapies and supportive management, the entry of novel pipeline agents such as AKP-009 could create a new treatment paradigm and stimulate market expansion over the forecast period.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in PMOS (2022–2036 Forecast)

The PMOS market (2022–2036 forecast) is expected to evolve from a symptom-based treatment paradigm dominated by off-label therapies toward a more targeted therapeutic landscape addressing the underlying hormonal, metabolic, and reproductive abnormalities associated with the disorder.

• Androgen Receptor (AR) Modulator: In PMOS, excessive androgen activity is a key pathological feature contributing to clinical manifestations such as hyperandrogenism, hirsutism, acne, ovulatory dysfunction, and metabolic abnormalities. By modulating androgen receptor signaling, AKP-009 has the potential to provide a targeted approach toward controlling androgen-driven disease mechanisms rather than only managing individual symptoms.

Unlike currently used off-label therapies such as oral contraceptives and anti-androgens (e.g., spironolactone), which primarily provide symptomatic relief, an androgen receptor–targeted approach may offer a more mechanism-based strategy for patients with androgen-dominant PMOS phenotypes.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the PMOS drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

As no approved PMOS-specific treatments currently exist, upcoming innovations are expected to gain adoption by demonstrating advantages over existing off-label approaches through improved efficacy, targeted mechanism of action, and broader impact across reproductive and metabolic outcomes.

Among pipeline assets, AKP-009 represents an early-stage opportunity as a preclinical candidate designed to explore a targeted therapeutic approach for PMOS. Successful clinical development of such disease-modifying agents could significantly reshape the treatment landscape by shifting management away from symptom control toward mechanism-based intervention.

Despite a relatively limited pipeline, the PMOS market is expected to evolve as a small number of emerging therapies target both the endocrine and metabolic components of the disease. The uptake in the PMOS market is expected to be increasingly driven by the ability of novel therapies to provide comprehensive benefits, including improved hormonal balance, metabolic control, fertility outcomes, and long-term disease risk reduction. Therapies offering broad clinical utility across diverse PMOS phenotypes are likely to achieve stronger adoption as physicians increasingly seek personalized treatment options for this heterogeneous disorder.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report….

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Therapies Price Scenario & Trends 

Pricing and analogue assessment of PMOS therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Polyendocrine Metabolic Ovarian Syndrome (PMOS) 

To keep up with PMOS market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the PMOS emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in PMOS, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at the country level. Centers such as University of Alabama at Birmingham, University Hospital Heidelberg, and The University of Tokyo etc. were contacted. Their opinion helps understand and validate current and emerging PMOS therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in PMOS.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT analysis of PMOS, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of PMOS, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the PMOS market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM PMOS market. 

Report Insights

• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Patient Population Forecast
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Therapeutics Market Size 
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Pipeline Analysis
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market Size and Trends
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Treatment Addressable Market (TAM)
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Competitve Landscape
• Polyendocrine Metabolic Ovarian Syndrome (PMOS)) Major Companies Insights
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Price Trends and Analogue Assessment
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Therapies Drug Adoption/Uptake
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Therapies Peak Patient Share Analysis

Report Assessment

• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Current Treatment Practices
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Unmet Needs
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Clinical Development Analysis
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Emerging Drugs Product Profiles
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Market attractiveness
• Polyendocrine Metabolic Ovarian Syndrome (PMOS) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

Market Insights

• What was the PMOS market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of PMOS?
• What are the disease risks, burdens, and unmet needs of PMOS? What will be the growth opportunities across the 7MM concerning the patient population with PMOS?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of PMOS? What are the current guidelines for treating PMOS in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the PMOS market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.